Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor

Augusto Chiari, Pierpaolo Lovisolo, Gianpaolo Fogliatto, Daniele Fancelli, Giancarlo Ghiselli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Rabbits fed a wheat starch casein diet develop hypercholesterolaemia characterized by the plasma elevation of low density lipoprotein (LDL) that is caused by oversecretion of apoB-100 containing lipoproteins by the liver and by the suppression of the EDTA-sensitive hepatic β- very low density lipoprotein (VLDL)-LDL receptor. In this study, the effect of FCE 27677 ((-)N-[-2,6-bis(1-methylethyl)phenyl]-N' 4,5-dimethyl-dioxolan-2-yl]methylurea) a novel potent systemic acylCoA:cholesterol acetyltransferase (ACAT, EC 2.3.1.26) inhibitor, has been evaluated. When New Zealand White rabbits were fed with casein for 4 weeks, LDL cholesterol increased from 14 ± 3 mg/dl-1 to 77 ± 6 mg/dl-1. By contrast the animals receiving FCE 27677 (10 mg kg-1 d-1) mixed with the casein diet maintained a normal LDL concentration (22 ± 3 mg dl-1). This hypolipidaemic effect was also observed when rabbits previously made hypercholesterolaemic by being fed casein for 4 weeks were then treated for a month with FCE 27677. [125I]LDL plasma turnover studies and [125I]LDL binding studies to liver membranes were carried out with the purpose of investigating the mechanism of action of the drug. The LDL apoB-100 production rate in chow-fed, casein-fed, and casein-fed rabbits receiving FCE 27677, was respectively 10.5, 22.4, and 12.5 mg kg-1 d-1. The turnover rate of [125I]LDL in the animals receiving the drug was not, however, different from that in the rabbits fed the casein diet alone (2.381 vs 2.079 pools d-1). Both values were lower than that in chow-fed animals (3.271 pools d-1. FCE 27677 did not normalize the activity of the hepatic β-VLDL-LDL EDTA-sensitive receptor which is suppressed by casein feeding. Altogether the results are consistent with the idea that FCE 27677 by acting through inhibition of the cholesterol esterification in the liver normalizes the LDL synthetic rate. ACAT inhibitors may be useful drugs for the treatment of human dyslipoproteinaemia secondary to derangement of the apoB-100 synthetic rate.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalPharmacological Research
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 1996

Fingerprint

Dyslipidemias
Caseins
LDL Lipoproteins
Rabbits
Apolipoprotein B-100
Liver
VLDL Lipoproteins
Diet
Edetic Acid
Cholesterol
Pharmaceutical Preparations
Acetyltransferases
FCE 27677
LDL Receptors
Esterification
Hypercholesterolemia
Starch
LDL Cholesterol
Lipoproteins
Triticum

Keywords

  • ACAT inhibition
  • apoB-100
  • Casein
  • Dyslipoproteinaemia
  • Rabbit

ASJC Scopus subject areas

  • Pharmacology

Cite this

Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor. / Chiari, Augusto; Lovisolo, Pierpaolo; Fogliatto, Gianpaolo; Fancelli, Daniele; Ghiselli, Giancarlo.

In: Pharmacological Research, Vol. 33, No. 3, 03.1996, p. 181-189.

Research output: Contribution to journalArticle

Chiari, Augusto ; Lovisolo, Pierpaolo ; Fogliatto, Gianpaolo ; Fancelli, Daniele ; Ghiselli, Giancarlo. / Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor. In: Pharmacological Research. 1996 ; Vol. 33, No. 3. pp. 181-189.
@article{8d596b71a27d4088969571b9990d6b7c,
title = "Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor",
abstract = "Rabbits fed a wheat starch casein diet develop hypercholesterolaemia characterized by the plasma elevation of low density lipoprotein (LDL) that is caused by oversecretion of apoB-100 containing lipoproteins by the liver and by the suppression of the EDTA-sensitive hepatic β- very low density lipoprotein (VLDL)-LDL receptor. In this study, the effect of FCE 27677 ((-)N-[-2,6-bis(1-methylethyl)phenyl]-N' 4,5-dimethyl-dioxolan-2-yl]methylurea) a novel potent systemic acylCoA:cholesterol acetyltransferase (ACAT, EC 2.3.1.26) inhibitor, has been evaluated. When New Zealand White rabbits were fed with casein for 4 weeks, LDL cholesterol increased from 14 ± 3 mg/dl-1 to 77 ± 6 mg/dl-1. By contrast the animals receiving FCE 27677 (10 mg kg-1 d-1) mixed with the casein diet maintained a normal LDL concentration (22 ± 3 mg dl-1). This hypolipidaemic effect was also observed when rabbits previously made hypercholesterolaemic by being fed casein for 4 weeks were then treated for a month with FCE 27677. [125I]LDL plasma turnover studies and [125I]LDL binding studies to liver membranes were carried out with the purpose of investigating the mechanism of action of the drug. The LDL apoB-100 production rate in chow-fed, casein-fed, and casein-fed rabbits receiving FCE 27677, was respectively 10.5, 22.4, and 12.5 mg kg-1 d-1. The turnover rate of [125I]LDL in the animals receiving the drug was not, however, different from that in the rabbits fed the casein diet alone (2.381 vs 2.079 pools d-1). Both values were lower than that in chow-fed animals (3.271 pools d-1. FCE 27677 did not normalize the activity of the hepatic β-VLDL-LDL EDTA-sensitive receptor which is suppressed by casein feeding. Altogether the results are consistent with the idea that FCE 27677 by acting through inhibition of the cholesterol esterification in the liver normalizes the LDL synthetic rate. ACAT inhibitors may be useful drugs for the treatment of human dyslipoproteinaemia secondary to derangement of the apoB-100 synthetic rate.",
keywords = "ACAT inhibition, apoB-100, Casein, Dyslipoproteinaemia, Rabbit",
author = "Augusto Chiari and Pierpaolo Lovisolo and Gianpaolo Fogliatto and Daniele Fancelli and Giancarlo Ghiselli",
year = "1996",
month = "3",
doi = "10.1006/phrs.1996.0025",
language = "English",
volume = "33",
pages = "181--189",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "3",

}

TY - JOUR

T1 - Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor

AU - Chiari, Augusto

AU - Lovisolo, Pierpaolo

AU - Fogliatto, Gianpaolo

AU - Fancelli, Daniele

AU - Ghiselli, Giancarlo

PY - 1996/3

Y1 - 1996/3

N2 - Rabbits fed a wheat starch casein diet develop hypercholesterolaemia characterized by the plasma elevation of low density lipoprotein (LDL) that is caused by oversecretion of apoB-100 containing lipoproteins by the liver and by the suppression of the EDTA-sensitive hepatic β- very low density lipoprotein (VLDL)-LDL receptor. In this study, the effect of FCE 27677 ((-)N-[-2,6-bis(1-methylethyl)phenyl]-N' 4,5-dimethyl-dioxolan-2-yl]methylurea) a novel potent systemic acylCoA:cholesterol acetyltransferase (ACAT, EC 2.3.1.26) inhibitor, has been evaluated. When New Zealand White rabbits were fed with casein for 4 weeks, LDL cholesterol increased from 14 ± 3 mg/dl-1 to 77 ± 6 mg/dl-1. By contrast the animals receiving FCE 27677 (10 mg kg-1 d-1) mixed with the casein diet maintained a normal LDL concentration (22 ± 3 mg dl-1). This hypolipidaemic effect was also observed when rabbits previously made hypercholesterolaemic by being fed casein for 4 weeks were then treated for a month with FCE 27677. [125I]LDL plasma turnover studies and [125I]LDL binding studies to liver membranes were carried out with the purpose of investigating the mechanism of action of the drug. The LDL apoB-100 production rate in chow-fed, casein-fed, and casein-fed rabbits receiving FCE 27677, was respectively 10.5, 22.4, and 12.5 mg kg-1 d-1. The turnover rate of [125I]LDL in the animals receiving the drug was not, however, different from that in the rabbits fed the casein diet alone (2.381 vs 2.079 pools d-1). Both values were lower than that in chow-fed animals (3.271 pools d-1. FCE 27677 did not normalize the activity of the hepatic β-VLDL-LDL EDTA-sensitive receptor which is suppressed by casein feeding. Altogether the results are consistent with the idea that FCE 27677 by acting through inhibition of the cholesterol esterification in the liver normalizes the LDL synthetic rate. ACAT inhibitors may be useful drugs for the treatment of human dyslipoproteinaemia secondary to derangement of the apoB-100 synthetic rate.

AB - Rabbits fed a wheat starch casein diet develop hypercholesterolaemia characterized by the plasma elevation of low density lipoprotein (LDL) that is caused by oversecretion of apoB-100 containing lipoproteins by the liver and by the suppression of the EDTA-sensitive hepatic β- very low density lipoprotein (VLDL)-LDL receptor. In this study, the effect of FCE 27677 ((-)N-[-2,6-bis(1-methylethyl)phenyl]-N' 4,5-dimethyl-dioxolan-2-yl]methylurea) a novel potent systemic acylCoA:cholesterol acetyltransferase (ACAT, EC 2.3.1.26) inhibitor, has been evaluated. When New Zealand White rabbits were fed with casein for 4 weeks, LDL cholesterol increased from 14 ± 3 mg/dl-1 to 77 ± 6 mg/dl-1. By contrast the animals receiving FCE 27677 (10 mg kg-1 d-1) mixed with the casein diet maintained a normal LDL concentration (22 ± 3 mg dl-1). This hypolipidaemic effect was also observed when rabbits previously made hypercholesterolaemic by being fed casein for 4 weeks were then treated for a month with FCE 27677. [125I]LDL plasma turnover studies and [125I]LDL binding studies to liver membranes were carried out with the purpose of investigating the mechanism of action of the drug. The LDL apoB-100 production rate in chow-fed, casein-fed, and casein-fed rabbits receiving FCE 27677, was respectively 10.5, 22.4, and 12.5 mg kg-1 d-1. The turnover rate of [125I]LDL in the animals receiving the drug was not, however, different from that in the rabbits fed the casein diet alone (2.381 vs 2.079 pools d-1). Both values were lower than that in chow-fed animals (3.271 pools d-1. FCE 27677 did not normalize the activity of the hepatic β-VLDL-LDL EDTA-sensitive receptor which is suppressed by casein feeding. Altogether the results are consistent with the idea that FCE 27677 by acting through inhibition of the cholesterol esterification in the liver normalizes the LDL synthetic rate. ACAT inhibitors may be useful drugs for the treatment of human dyslipoproteinaemia secondary to derangement of the apoB-100 synthetic rate.

KW - ACAT inhibition

KW - apoB-100

KW - Casein

KW - Dyslipoproteinaemia

KW - Rabbit

UR - http://www.scopus.com/inward/record.url?scp=0030108524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030108524&partnerID=8YFLogxK

U2 - 10.1006/phrs.1996.0025

DO - 10.1006/phrs.1996.0025

M3 - Article

C2 - 8880889

AN - SCOPUS:0030108524

VL - 33

SP - 181

EP - 189

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 3

ER -